Last reviewed · How we verify
NCT05571137
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
trial in Cytomegalovirus (CMV) in 118 participants. Completed in 31 January 2024.
31 January 2024
Quick facts
| Lead sponsor | Takeda |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 118 |
| Start date | 31 May 2023 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 11 locations across Greece, Belgium, Austria, Serbia, Israel, Poland, Canada |
Conditions studied
- Cytomegalovirus (CMV) — all drugs for Cytomegalovirus (CMV) →
Sponsor
Takeda — full company profile →
Who can join
18 and older, any sex, with Cytomegalovirus (CMV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe \[EU\] and Canada \[CAN\]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05571137
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cytomegalovirus (CMV)
Currently open trials in the same condition.
- NCT07014319 — Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies · Phase 2 · recruiting
- NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT06677892 — A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium · recruiting
- NCT06439342 — A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections · Phase 3 · recruiting
Other Takeda trials
Trials by the same sponsor.
- NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
- NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
- NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
- NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
- NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05571137 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Takeda
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05571137.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing